8-K: ZIVO Bioscience Algae Tech Shows Breakthroughs in Human & Animal Health

ZIVO Bioscience's CEO highlights significant progress in human nutrition and animal health, driven by proprietary algae technology with superior antioxidant activity and immune-modulating effects.

Summary

• ZIVO Bioscience has achieved breakthrough scientific validation for its proprietary algae technology in human nutrition and animal health.
• An independent biochemical analysis revealed the algae contains substantial levels of key antioxidants like Superoxide Dismutase (SOD) and catalase, along with a rich profile of vitamins, carotenoids, and proteins.
• The algae demonstrated nearly double the activity of SOD in a side-by-side comparison to a competing algae-based product.
• In animal health, the algae culture provides critical ingredients for non-antibiotic animal feed, boosting immune systems to prevent or delay viral, bacterial, and parasitic diseases.
• Controlled university challenge trials in poultry infected with avian influenza showed delayed transmission, lower viral shedding, and faster immune response in birds receiving ZIVO's algae-derived immune modulator.
• The company is targeting multi-billion dollar markets, including the global animal feed market (valued at $465.65 billion in 2024, projected to reach $705.15 billion by 2034) and the antibiotic-free livestock feed segment (valued at $4.5 billion in 2024, projected to reach $8.9 billion by 2033 at an 8.2% CAGR).
• Management and the board have personally invested in the company, believing the current share price undervalues its scientific breakthroughs and market opportunities.
• ZIVO faces liquidity challenges but is optimistic about overcoming them through capital raising efforts.

Sentiment

Score: 7

Explanation: The filing presents significant scientific breakthroughs and strong market validation in both human nutrition and animal health, with promising commercial discussions. Management's personal investment signals confidence. However, the acknowledged liquidity challenges temper the overall positive sentiment, indicating a need for successful capital raising to fully realize potential.

Positives

• Proprietary algae technology demonstrated nearly double the Superoxide Dismutase (SOD) activity compared to a competing product in an independent biochemical analysis.
• Algae product contains substantial levels of key antioxidants (SOD, catalase), beta-carotene, lutein, vitamins, carotenoids, and proteins, positioning it as a powerful natural antioxidant source.
• Successful university challenge trials in poultry infected with avian influenza showed delayed transmission, lower viral shedding, and faster immune response with ZIVO's algae-derived immune modulator.
• Active discussions are underway with major nutraceutical clients, with anticipated significant commercial commitments in the near term expected to materially increase human health revenues.
• Strong interest from global animal health companies validates market demand and superior performance of the algae technology.
• Plans to negotiate with major companion animal product companies, significantly expanding the addressable market.
• Targeting multi-billion dollar markets, including the antibiotic-free livestock feed segment ($4.5 billion in 2024, projected to grow to $8.9 billion by 2033 at an 8.2% CAGR).
• Management and board members have personally invested in the company, signaling strong conviction in its value and future prospects.

Negatives

• The company continues to face liquidity challenges.

Risks

• Strategic partnerships may not facilitate the commercialization or market acceptance of products.
• Inability to increase production sufficiently to meet demand.
• Products may not be ready for commercialization in a timely manner or at all.
• Products may not perform as expected based on results of preclinical and clinical trials.
• Ability to raise additional funds is uncertain.
• Uncertainties inherent in the development process of products.
• Changes in regulatory requirements or decisions of regulatory authorities.
• Ability to protect intellectual property rights.

Future Outlook

ZIVO is entering an exciting phase of execution and growth, with expectations for significant near-term growth from new product commitments in the nutraceutical market. Animal health initiatives are anticipated to provide exceptional long-term opportunities in markets experiencing urgent global demand. The company is optimistic about overcoming liquidity challenges through capital raising efforts and has several confidential studies underway with potential for significant market impact and long-term growth.

Management Comments

• "This past year has been one of the most pivotal in our history."
• "Our proprietary algae platform has delivered breakthrough results that position ZIVO at the forefront of two rapidly growing markets – human nutrition and animal health."
• "We believe this breakthrough definitively sets us apart in the nutraceutical marketplace and positions us as an attractive partner for leading companies seeking validated, high-performance natural ingredients."
• "We anticipate significant commercial commitments in the near term that will materially increase our human health revenues."
• "Our data has proven exceptionally compelling in the animal health sector."
• "We intend to negotiate with major companion animal product companies, expanding our addressable market significantly."
• "We believe the convergence of regulatory pressure against antibiotic overuse, consumer demand for natural products, and our scientifically validated superior performance creates an exceptional market opportunity."
• "We have decided it is time to redouble our efforts to help the world understand what ZIVO does and recognize our unique investment opportunity."
• "We believe this demonstrates our deep conviction that today’s share price undervalues our scientific breakthroughs, expanding market opportunities, and pending commercial agreements that we believe will drive long-term shareholder value."
• "While ZIVO continues to face liquidity challenges, we are optimistic we can overcome those through capital raising efforts."

Industry Context

ZIVO Bioscience is strategically positioned to capitalize on major industry trends, including increasing regulatory pressure against antibiotic overuse in livestock and growing consumer demand for natural, antibiotic-free products. Its algae-derived solutions directly address these global challenges, offering a natural alternative to traditional antibiotics and meeting the rising demand for immune-boosting nutraceuticals in both human and animal health markets. The company's focus aligns with the expansion of the global animal feed, veterinary supplements, and pet supplements markets, which are all experiencing significant growth.

Comparison to Industry Standards

• ZIVO's algae product demonstrated nearly double the activity of Superoxide Dismutase (SOD) in a side-by-side comparison to a competing algae-based product, indicating superior antioxidant performance.
• The company's successful trials in poultry against avian influenza demonstrate real-world potential to slow the spread of one of the industry's most devastating diseases, offering a non-antibiotic solution in a market driven by the need for alternatives.

Related Party Transactions

• Management and board members have personally invested in the Company, demonstrating their deep conviction in its scientific breakthroughs, expanding market opportunities, and pending commercial agreements.

Stakeholder Impact

• Shareholders: Potential for significant long-term value creation due to scientific breakthroughs, expanding market opportunities, and anticipated commercial agreements. Management and board's personal investment signals confidence.
• Customers (Human Nutrition): Access to a powerful natural source of antioxidants with superior performance compared to competitors.
• Customers (Animal Health): Access to non-antibiotic solutions that boost animal immune systems, helping prevent diseases and addressing regulatory and consumer demands.
• Industry: ZIVO's technology offers a solution to the pressing global challenge of reducing antibiotic dependence in agriculture.

Next Steps

• Finalize significant commercial commitments with major nutraceutical clients.
• Negotiate with major companion animal product companies.
• Continue and conclude several confidential studies currently underway.
• Execute capital raising efforts to address liquidity challenges.
• Increase production to meet anticipated demand.

Key Dates

Recommendation

The filing details significant scientific breakthroughs in proprietary algae technology, demonstrating superior antioxidant activity for human nutrition and effective immune modulation in animal health, particularly against avian influenza. These validated results position ZIVO to capture substantial market share in multi-billion dollar, high-growth segments like antibiotic-free animal feed and natural supplements. Active commercial discussions and management's personal investment underscore strong conviction. While liquidity challenges exist, the potential for significant value creation from these advancements, coupled with a clear strategic market position, makes the stock an attractive 'buy' for investors willing to monitor capital raising progress.

Keywords

ZIVO Bioscience, algae technology, human nutrition, animal health, nutraceuticals, antioxidants, Superoxide Dismutase, SOD, immune modulator, avian influenza, antibiotic-free feed, veterinary supplements, pet supplements, biotech, agtech